204 related articles for article (PubMed ID: 26753956)
1. Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.
Hao W; Zhang X; Xiu B; Yang X; Hu S; Liu Z; Duan C; Jin S; Ying X; Zhao Y; Han X; Hao X; Fan Y; Johnson H; Meng D; Persson JL; Zhang H; Feng X; Huang Y
Tumour Biol; 2016 Jul; 37(7):8909-16. PubMed ID: 26753956
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Serum Integrin αvβ3 & Vitronectin in the Early Diagnosis of Breast Cancer.
Radwan AF; Ismael OE; Fawzy A; El-Mesallamy HO
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307158
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
4. Analysis of blood markers for early breast cancer diagnosis.
Bayo J; Castaño MA; Rivera F; Navarro F
Clin Transl Oncol; 2018 Apr; 20(4):467-475. PubMed ID: 28808872
[TBL] [Abstract][Full Text] [Related]
5. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
8. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
10. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
12. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
13. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
15. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.
Lian M; Zhang C; Zhang D; Chen P; Yang H; Yang Y; Chen S; Hong G
J Clin Lab Anal; 2019 Jun; 33(5):e22875. PubMed ID: 30843272
[TBL] [Abstract][Full Text] [Related]
16. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.
Kulasingam V; Zheng Y; Soosaipillai A; Leon AE; Gion M; Diamandis EP
Int J Cancer; 2009 Jul; 125(1):9-14. PubMed ID: 19322904
[TBL] [Abstract][Full Text] [Related]
17. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.
Fu Y; Li H
Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic roles of serum vitronectin in hepatitis B-related hepatocellular carcinoma.
Yang XP; Zhou LX; Yang QJ; Liu L; Cai Y; Ma SL
Cancer Biomark; 2016 Sep; 17(3):271-279. PubMed ID: 27802203
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.
Li P; He Q; Luo C; Qian L
Int J Clin Exp Pathol; 2015; 8(1):660-4. PubMed ID: 25755760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
